0. DOCID:23103 SCORE: 0.00353139372821189
DOCNO: 8912548
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: blood
QUALIFIER: blood
QUALIFIER: drug therapy
QUALIFIER: blood
AUTHOR: G J Rustin GJ
AUTHOR: T G Quinnell TG
AUTHOR: J Johnson J
AUTHOR: H Clarke H
AUTHOR: A E Nelstrop AE
AUTHOR: W Bollag W
AFFILIATION: Department of Medical Oncology, Mount Vernon Centre for Cancer Treatment, Mount Vernon Hospital, Northwood, Middlesex, UK.
PUBTYPE: Clinical Trial
PUBTYPE: Journal Article
PUBTYPE: Multicenter Study
JOURNALTITLE: British journal of cancer.
COUNTRY: SCOTLAND
TITLE: Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer.
PUBDATE: 19961101
Twenty-two asymptomatic women with rising CA 125 levels after chemotherapy for ovarian cancer were entered into a trial of isotretinoin combined with calcitriol. Tumours were evaluated according to precise criteria based on serial CA 125 levels and by comparing regression slopes of CA 125 before and during therapy. There was no evidence based on CA 125 of any responses or significant change in tumour growth rate.


1. DOCID:23097 SCORE: 0.00353137973944471
DOCNO: 8051769
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Prostatectomy
QUALIFIER: surgery
QUALIFIER: surgery
AUTHOR: H B Heidenberg HB
AUTHOR: J W Moul JW
AUTHOR: F K Mostofi FK
AUTHOR: D G McLeod DG
AFFILIATION: Urology Service, Walter Reed Army Medical Center, Bethesda, Maryland.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: The Journal of urology.
COUNTRY: UNITED STATES
TITLE: Clinically detected carcinoma of the prostate treated by radical prostatectomy in a 29-year-old man.
PUBDATE: 19940901
Prostate cancer is rare in young adults and when clinically detected it has been invariably locally or distantly advanced, undifferentiated and exhibiting aggressive behavior. To our knowledge no previous report documents clinically detected and localized disease amenable to curative surgery in a young adult. We report on a 29-year-old man with clinically detected, moderately differentiated adenocarcinoma of the prostate who was treated by nerve sparing radical retropubic prostatectomy. The patient was disease-free and morbidity-free 30 months after treatment.


2. DOCID:23004 SCORE: 0.00338622062082413
DOCNO: 7609971
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Cholecystectomy, Laparoscopic
QUALIFIER: diagnosis
QUALIFIER: diagnosis
AUTHOR: J Sándor J
AUTHOR: M Ihász M
AUTHOR: T Fazekas T
AUTHOR: J Regöly-Mérei J
AUTHOR: J Bátorfi J
AFFILIATION: III. sz. Sebészeti Klinika, Semmelweis Orvostudományi Egyetem, Budapest.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Orvosi hetilap.
COUNTRY: HUNGARY
TITLE: [Laparoscopic cholecystectomy and cancer of the gallbladder]
PUBDATE: 19950701
Performing a series of 960 laparoscopic cholecystectomies we have removed 3 unsuspected gallbladder cancers. In one case we have observed the development of trocar site abdominal wall metastasis twice. After resection and reresection of the metastases the patient is symptom-free in the 14th month. During laparoscopic cholecystectomy if there is a suspicion of gallbladder cancer we have to manipulate with special care to avoid rupture of the gallbladder. In doubtful cases frozen section is mandatory. If the malignant process extends over the serosal layer--conversion and radical-extended operation is recommended.


3. DOCID:22807 SCORE: 0.00305553953124535
DOCNO: 8691599
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Genes, Tumor Suppressor
DESCRIPTOR: Oncogenes
QUALIFIER: analysis
AUTHOR: H Kondo H
AUTHOR: A Nobuoka A
AFFILIATION: Division of G1 oncology, National Cancer Center Hospital.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Nippon rinsho. Japanese journal of clinical medicine.
COUNTRY: JAPAN
TITLE: [Clinical application of oncogene and antioncogene as a tumor marker]
PUBDATE: 19960601
Since it is generally accepted that neoplasm is developed by accumulation of abnormalities in oncogenes and antioncogenes, these genetic analysis would be useful as new tumor markers. The present clinical applications of genetic analysis of oncogenes are as follows, 1) diagnosis of neoplasm (early detection, differential diagnosis for borderline lesion), 2) speculation of the prognosis of a cancer patient and prediction of chemosensitivity and, 3) establishment of high risk group of cancer. In regard to clinical practice, a medical doctor take care of scientific interpretation of genetic examinations as well as ethical problems.


4. DOCID:21386 SCORE: 0.00296238725399393
DOCNO: 8713631
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: complications
QUALIFIER: drug therapy
AUTHOR: W M O'Neill WM
AFFILIATION: Dept of Palliative Medicine, Bristol Oncology Centre, England.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Middle East journal of anesthesiology.
COUNTRY: LEBANON
TITLE: Cancer pain.
PUBDATE: 19960201
An accurate assessment and where possible a precise diagnosis of the underlying mechanism in necessary for the effective management of pain in cancer. The majority of patients respond to oral analgesics, and the range of drugs required is not vast. Adjuvant analgesic drugs will be needed for the treatment of bone pain, visceral pain and neuropathic pain. For the remaining patients who present with difficult and occasionally intractable pain, a multidisciplinary approach using drug and non-drug measures will usually allow significant relief of symptoms.


5. DOCID:23621 SCORE: 0.00281789015443818
DOCNO: 8903298
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Terminal Care
QUALIFIER: complications
QUALIFIER: secondary
QUALIFIER: pathology
QUALIFIER: drug therapy
QUALIFIER: therapeutic use
QUALIFIER: therapeutic use
AUTHOR: S Ramani S
AUTHOR: A B Karnad AB
AFFILIATION: Department of Internal Medicine, Alvin C. York Veterans Affairs Medical Center, Murfreesboro, Tenn, USA.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Southern medical journal.
COUNTRY: UNITED STATES
TITLE: Long-term subcutaneous infusion of midazolam for refractory delirium in terminal breast cancer.
PUBDATE: 19961101
We describe the case of a 56-year-old woman with terminal metastatic breast cancer who had delirium in the form of frightening hallucinations, paranoid delusions, and nightmares resulting in violent agitation. During this period, her bone pains from metastases were well controlled with narcotic analgesics, but her delirium proved refractory to standard doses of drugs such as lorazepam, diazepam, and haloperidol. We report the use of a subcutaneous infusion of midazolam at home and its effectiveness in control of her delirium after other drugs had failed.


6. DOCID:23811 SCORE: 0.00280038538901295
DOCNO: 9246403
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: radiotherapy
QUALIFIER: adverse effects
AUTHOR: J Moni J
AUTHOR: D Nori D
AFFILIATION: Department of Radiation Oncology, New York Hospital, New York, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Chest surgery clinics of North America.
COUNTRY: UNITED STATES
TITLE: The pitfalls and complications of radiation therapy for esophageal carcinoma.
PUBDATE: 19970801
Radiation therapy is an important part of the management of esophageal cancer. Effective radiation therapy, however, requires careful evaluation of the tumor and the patient, cognizance of the tolerance of normal tissues in the area to the type of chemotherapy or surgical procedure employed, detailed planning, and streamlined delivery. When combining radiation therapy with other modalities of cancer treatment, physicians of both disciplines must be aware of the ability of one modality to potentiate the toxicity of the other. Therapy prescribed with the intention to cure and achieve long-term survival must be planned with consideration for the quality of life of the patient.


7. DOCID:22983 SCORE: 0.00279190824421638
DOCNO: 8965359
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Gastroscopy
QUALIFIER: methods
QUALIFIER: therapeutic use
QUALIFIER: therapy
AUTHOR: S Otsuka S
AFFILIATION: First Department of Internal Medicine, Toho University School of Medicine.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Nippon rinsho. Japanese journal of clinical medicine.
COUNTRY: JAPAN
TITLE: [Endoscopic treatment of early gastric cancer with laser and laserthermia using Nd : YAG laser]
PUBDATE: 19960501
As a therapeutic modality for early gastric cancer, endoscopic laser treatment is indicated in cases where the tumor is an intramucosal carcinoma, the macroscopic type is either I, IIa, or IIc(Ul(-)), and the diameter of the tumor is less than 10 mm. Type I tumors with less than 15 mm diameter and type IIa tumors with less than 20 mm diameter can be included in this indication. Depressed lesions should be treated carefully. Endoscopic laser treatment may be considered for patients who are not candidates for surgery or who refuse surgery.


8. DOCID:23953 SCORE: 0.00276178908616192
DOCNO: 7569029
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: physiopathology
AUTHOR: H P Rodemann HP
AUTHOR: M Bamberg M
AFFILIATION: Department of Radiotherapy, Eberhard-Karls-University, Tübingen, Germany.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
COUNTRY: IRELAND
TITLE: Cellular basis of radiation-induced fibrosis.
PUBDATE: 19950501
Fibrosis is a common sequela of both cancer treatment by radiotherapy and accidental irradiation and has been described in many tissues including skin, lung, heart and liver. The underlying mechanisms of the radiation-induced fibrosis still remain to be resolved. In the present review we tried to illustrate the basic cellular mechanisms of radiation-induced fibrosis based on the newest findings arising from molecular radiobiology and cell biology. Based on these findings the cellular mechanism of radiation-induced fibrosis can be seen as a multicellular process involving various interacting cell systems in the target organ resulting in the fibrotic phenotype of the fibroblast/fibrocyte cell system.


9. DOCID:21796 SCORE: 0.00271739787435325
DOCNO: 9087202
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: diagnosis
QUALIFIER: pathology
QUALIFIER: diagnosis
QUALIFIER: pathology
QUALIFIER: diagnosis
QUALIFIER: pathology
AUTHOR: R M Gore RM
AFFILIATION: Department of Radiology, Evanston Hospital-McGaw Medical Center of Northwestern University, Illinois, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Radiologic clinics of North America.
COUNTRY: UNITED STATES
TITLE: Esophageal cancer. Clinical and pathologic features.
PUBDATE: 19970301
Carcinoma of the esophagus remains one of the most lethal of all cancers. In the past, squamous cell carcinomas accounted for over 95% of esophageal malignancies. Over the past two decades, however, there has been a dramatic increase in the incidence of adenocarcinoma arising in columnar cell-lined Barrett's mucosa, accounting for up to 34% of all esophageal cancers in some areas. This article discusses the different demographic, pathologic, therapeutic, and prognostic features of squamous cell and adenocarcinoma of the esophagus.


10. DOCID:23208 SCORE: 0.00268805127914346
DOCNO: 9328182
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: chemistry
QUALIFIER: analogs & derivatives
AUTHOR: A Collins A
AUTHOR: J Cadet J
AUTHOR: B Epe B
AUTHOR: C Gedik C
AFFILIATION: Rowett Research Institute, Bucksburn, Aberdeen, UK.
PUBTYPE: Congresses
JOURNALTITLE: Carcinogenesis.
COUNTRY: ENGLAND
TITLE: Problems in the measurement of 8-oxoguanine in human DNA. Report of a workshop, DNA oxidation, held in Aberdeen, UK, 19-21 January, 1997.
PUBDATE: 19970901
Oxidative DNA damage is widely believed to play a role in cancer aetiology. It is therefore important to be able to assess it, both as an index of cancer risk, and in experiments to test agents with a potential to reduce oxidative damage, such as dietary antioxidants. However, there is an alarming discordance in estimates of concentrations of oxidative damage in human DNA, largely attributable to the kind of method used to measure it. A meeting was held recently at the Rowett Research Institute in Aberdeen to address this problem.


11. DOCID:21780 SCORE: 0.00258135244983246
DOCNO: 8946875
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: adverse effects
QUALIFIER: drug therapy
QUALIFIER: adverse effects
QUALIFIER: chemically induced
QUALIFIER: drug therapy
AUTHOR: H Gogas H
AUTHOR: D Fennelly D
AFFILIATION: Gynecological Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Gynecologic oncology.
COUNTRY: UNITED STATES
TITLE: Avascular necrosis following extensive chemotherapy and dexamethasone treatment in a patient with advanced ovarian cancer: case report and review of the literature.
PUBDATE: 19961201
Avascular necrosis has long been recognized as a complication of glucorticoid therapy. With the recent recognition of paclitaxel's activity in advanced ovarian cancer, increasing attention has been focused on the concomitant use of corticosteroid premedication and its associated morbidities. This report describes avascular necrosis occurring in a patient receiving chemotherapy with corticosteroid medication for advanced recurrent ovarian cancer.


12. DOCID:21750 SCORE: 0.00258135099037165
DOCNO: 8687349
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: radiotherapy
AUTHOR: J W Denham JW
AUTHOR: C S Hamilton CS
AUTHOR: S A Simpson SA
AUTHOR: M O'Brien M
AFFILIATION: Radiation Oncology Department, Mater Misericordiae Hospital, Newcastle, New South Wales, Australia.
PUBTYPE: Journal Article
JOURNALTITLE: Australasian radiology.
COUNTRY: AUSTRALIA
TITLE: Low dose rate teletherapy: updated tumour response.
PUBDATE: 19960501
This report presents an update of tumour response experience in patients with locally advanced head and neck cancer treated on the low dose rate teletherapy project at the Mater Misericordiae Hospital, Newcastle. Long-term progression-free survival figures are disappointing in all dose rate/total dose groupings and offer little encouragement that an improvement in therapeutic ratio can be achieved for head and neck cancer patients using teletherapy apparatus adjusted to treat at low and intermediate dose rates.


13. DOCID:22028 SCORE: 0.00257675981668777
DOCNO: 7916254
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Drug Resistance
DESCRIPTOR: Models, Biological
AUTHOR: J H Goldie JH
AFFILIATION: Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Lung cancer (Amsterdam, Netherlands)
COUNTRY: IRELAND
TITLE: Modelling the process of drug resistance.
PUBDATE: 19940301
Modelling the process of drug resistance can provide insight into such issues as the difference between intrinsic and acquired drug resistance. Other important biological questions such as whether resistance arises through selective or inducible events can also be addressed by reference to appropriate models. If drug resistant cells are produced by some type of inducible up regulation step then this has a number of qualifications for cancer chemotherapy. Selection theories of drug resistance imply that certain sequences of drugs will be superior to others something which can be tested by experiment.


14. DOCID:23563 SCORE: 0.00249561210496631
DOCNO: 7781407
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: metabolism
QUALIFIER: metabolism
QUALIFIER: metabolism
QUALIFIER: metabolism
AUTHOR: B E Johnson BE
AFFILIATION: Lung Cancer Biology Section, National Cancer Institute-Navy Medical Oncology Branch, National Naval Medical Center, Bethesda, Md., USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Chest.
COUNTRY: UNITED STATES
TITLE: Biologic and molecular prognostic factors--impact on treatment of patients with non-small cell lung cancer.
PUBDATE: 19950601
A wide range of genetic and phenotypic abnormalities have been identified in lung cancer. However, only a few are known to have an impact on patient outcome and thus may influence choice of therapy. Biologic and molecular factors known in this regard include the epidermal growth factor family and its receptors, markers of neuroendocrine differentiation in non-small cell lung cancer, and mutations of the ras gene family. None of these factors, however, can be considered a standard for selection of patients for therapy until additional information is gleaned from ongoing prospective studies.